Old Immunotherapy Shows Promise for Type 1 Diabetes: BCG Vaccine Reprograms White Blood Cells to Improve Blood Sugar Control

June 11, 2026 | Kolkata, West Bengal

A decades-old immunotherapy originally developed to prevent tuberculosis is demonstrating unexpected potential for treating type 1 diabetes. New clinical data show it can significantly improve blood sugar control by fundamentally reprogramming white blood cells. The findings, presented at the recent American Diabetes Association (ADA) 86th Scientific Sessions, offer fresh hope for the approximately 2 million children and adults in the United States living with this chronic autoimmune condition, which currently has no known cure.

Key Findings: Six BCG Shots Transform Blood Sugar Control

The updated research revealed that adults who developed type 1 diabetes during childhood and received six Bacillus Calmette-Guérin (BCG) vaccinations over a five-year period experienced a marked improvement in their long-term blood sugar management. Remarkably, this clinical stabilization occurred without relying on a functioning pancreas. Over the course of the multi-year observation period, participants were able to reduce their daily external insulin usage while achieving more stable, predictable blood sugar levels compared to their pre-treatment baselines.

The biological mechanism driving this clinical improvement is a major paradigm shift. Rather than simply suppressing the immune system, the immunotherapy physically reprograms the underlying metabolism of white blood cells. This shift forces these cells to change their primary fuel source:

• Pre-treatment state: Pathogenic white blood cells primarily metabolize fat.

• Post-treatment state: Reprogrammed white blood cells switch to rapidly consuming sugar (glucose) from the bloodstream for their primary energy needs.

This metabolic repurposing appears to act as a systemic “glucose sink,” restoring a form of natural blood sugar regulation in patients whose insulin-producing pancreatic beta cells have been entirely destroyed by autoimmune attacks.

Understanding Type 1 Diabetes and Current Limitations

Type 1 diabetes is an autoimmune condition where the body’s immune system mistakenly targets and destroys insulin-making beta cells in the pancreas. Unlike type 2 diabetes, which is highly correlated with insulin resistance and lifestyle factors, type 1 diabetes typically emerges abruptly during childhood or adolescence and requires lifelong, intensive insulin therapy.

Current management relies entirely on external insulin replacement delivered via multiple daily injections or continuous subcutaneous insulin pumps. However, this approach is far from a cure. Even with advanced continuous glucose monitors (CGMs) and automated delivery systems, many patients struggle to maintain target glycated hemoglobin ($HbA1c$) levels. They face daily, life-threatening risks of severe hypoglycemia (dangerously low blood sugar) or diabetic ketoacidosis.

According to data tracked by organizations like Johns Hopkins Medicine and the U.S. Food and Drug Administration (FDA), the disease impacts millions globally, emphasizing the urgent need for treatments that move beyond burdensome daily insulin calculation.

The BCG Vaccine: From TB Prevention to Metabolic Treatment

The Bacillus Calmette-Guérin vaccine is a 100-year-old live-attenuated bacterial strain originally designed for tuberculosis prevention. While it has been widely utilized in national immunization programs across Asia, Europe, and developing nations for generations, its application in type 1 diabetes represents a novel approach to autoimmune disease management.

Dr. Denise Faustman, Associate Professor of Medicine at Harvard Medical School and Director of the Immunobiology Laboratory at Massachusetts General Hospital, has spent decades investigating BCG’s off-target immunomodulatory effects. Her team initially discovered that individuals with type 1 diabetes possess white blood cells with abnormal metabolic profiles that shift away from normal glucose utilization.

“We found type one diabetics have white blood cells that eat fats. And guess what, your white blood cells eat sugar,” Dr. Faustman explained in a recent media briefing. “Being able to re-teach the white blood cells to eat sugar, in a regular fashion, can regulate blood sugars.”

Expert Commentary: Beyond Blocking Autoimmunity

The presentation at the ADA meeting represents an important evolution in how immunotherapies are evaluated for type 1 diabetes. Historically, research has focused entirely on preventing the immune system from destroying the pancreas. This study suggests that immunotherapy can do something more profound—it can alter systemic metabolism to mitigate the effects of that destruction.

Independent immunologists and endocrinologists not involved in the Faustman Lab research note that a dual-mechanism approach—halting localized immune destruction while simultaneously increasing systemic glucose consumption—could safely address multiple facets of the disease at once.

This systemic metabolic shift differs fundamentally from other experimental pipelines. For instance, monoclonal antibodies like mAb43 focus narrowly on sheltering surviving beta cells from immune attacks, an approach that is highly effective early on but cannot restore metabolic balance once the native beta cell mass has been entirely depleted.

Comparison of Emerging Type 1 Diabetes Pipelines

Study Limitations and Next Steps

Despite the promising long-term trends reported at the ADA scientific sessions, medical journalists and clinicians urge balanced caution. Because these data were presented at an annual medical conference rather than published as a full, peer-reviewed manuscript in a major journal, the complete statistical analyses, precise cohort sizes, and demographic breakdowns remain under academic review.

Furthermore, the duration required to see maximum therapeutic benefit from BCG is notable. The metabolic shift occurs gradually, requiring multiple vaccinations over a period of years rather than delivering an immediate clinical turnaround.

To address these limitations and satisfy regulatory hurdles, the Faustman Lab is currently enrolling participants for a multi-year, double-blind, placebo-controlled clinical trial specifically focusing on pediatric cohorts. This pediatric trial is essential, as researchers must confirm that the vaccine-induced metabolic reprogramming behaves safely and consistently across developing immune systems. Until these larger, blinded trials are completed, medical authorities emphasize that BCG vaccination should not be used off-label as a standard treatment for type 1 diabetes.

What This Means for Readers Today

For individuals living with type 1 diabetes and their families, these findings offer a strong signal of scientific progress, but they require patience. The protocol is not currently approved by regulatory bodies for general clinical use in diabetes care, and attempting to self-administer the BCG vaccine without strict medical supervision is highly dangerous.

Guidance for Patients and Caregivers:

• Maintain Established Protocols: Patients should continue adhering strictly to their prescribed endocrinology regimens, including regular blood sugar monitoring, carbohydrate counting, and scheduled insulin therapies.

• Explore Approved Alternatives for Severe Cases: For adult patients experiencing repeated, life-threatening episodes of hypoglycemia unawareness despite intensive management, options like the FDA-approved cellular therapy Lantidra are already commercially available.

• Follow Clinical Trials Safely: Families interested in these findings can monitor verified public trial registries to see if they qualify for upcoming pediatric or adult observational arms.

Ultimately, this milestone highlights an expanding era in modern medicine: the repurposing of century-old, cost-effective vaccines to address complex, modern chronic conditions.

Medical Disclaimer

Medical Disclaimer: This article is for informational purposes only and should not be considered medical advice. Always consult with qualified healthcare professionals before making any health-related decisions or changes to your treatment plan. The information presented here is based on current research and expert opinions, which may evolve as new evidence emerges.

References

• Reuters Health News Desk. “Older drug reprograms white blood cells, improves blood sugar in type 1 diabetes.” (Published June 10, 2026).